Source:http://linkedlifedata.com/resource/pubmed/id/18700567
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2008-8-14
|
pubmed:abstractText |
The efficacy and toxicity of treatment with carboplatin (AUC= 5)+ docetaxel (70mg/m2) were analyzed retrospectively in 27 elderly patients with advanced non-small-cell lung cancer (NSCLC) aged 70 years or more. The median age of the patients was 74 years (range, 70-83 years). The performance status (ECOG), clinical stage, and tumor histology in the patients were as follows: PS: PS 0, 12 patients; PS 1, 11 patients; PS 2, 4 patients; disease stage: stage IIIA, 5 patients; stage IIIB, 11 patients; stage IV, 11 patients; tumor histology: adenocarcinoma, 18 patients; squamous cell carcinoma, 9 patients. The median number of treatment cycles administered was 4. The median survival time was 11.1 months and the 1-year survival rate was 40.7%. The response rate was 33.3%. The major toxicities were leukopenia and neutropenia; grade 3/4 neutropenia occurred in 22 patients (81.5%). Nonhematologic toxicities were generally mild, including grade 3 anorexia in 13 patients (48.1%) and grade 3 febrile neutropenia in 9 patients (33.3%). No treatment-related deaths were observed. Thus, it was concluded that the combination of carboplatin + docetaxel is a feasible, well-tolerated, and effective regimen for fit elderly patients with NSCLC. Prospective studies comparing carboplatin + docetaxel with third-generation single-agent chemotherapy or non-platinum-based combination chemotherapy are needed to confirm the efficacy and safety of this drug combination.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1343-3490
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
516-21
|
pubmed:meshHeading |
pubmed-meshheading:18700567-Adenocarcinoma,
pubmed-meshheading:18700567-Aged,
pubmed-meshheading:18700567-Aged, 80 and over,
pubmed-meshheading:18700567-Antineoplastic Agents,
pubmed-meshheading:18700567-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18700567-Carboplatin,
pubmed-meshheading:18700567-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18700567-Carcinoma, Squamous Cell,
pubmed-meshheading:18700567-Female,
pubmed-meshheading:18700567-Humans,
pubmed-meshheading:18700567-Lung Neoplasms,
pubmed-meshheading:18700567-Male,
pubmed-meshheading:18700567-Retrospective Studies,
pubmed-meshheading:18700567-Taxoids
|
pubmed:year |
2008
|
pubmed:articleTitle |
[Combination chemotherapy with carboplatin and docetaxel for elderly patients with non-small-cell lung cancer].
|
pubmed:affiliation |
Department of Internal Medicine, Tokyo Dental College, Tokyo.
|
pubmed:publicationType |
Journal Article,
English Abstract
|